Global Pegfilgrastim Biosimilar Market Overview
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
The COVID-19 pandemic effect has been moderate on the overall pegfilgrastim market. COVID-19 has overall affected the speed of processes in clinical trials, but it’s predicted that, there will not be any near-term effect on approval processes by the regulatory bodies.
Pegfilgrastim Biosimilar Market Insights by Distribution Channel
The distribution channel includes hospital pharmacies, retail pharmacies, and mail-Order pharmacies. Hospital pharmacies have dominated the market, capturing over 50% market share in the global pegfilgrastim biosimilar market. Owing to increasing adoption of chemotherapy for cancer treatment across the globe, hospital pharmacies will be the most adoptive sector in the pegfilgrastim biosimilar market.
Regional Outlook of Pegfilgrastim Biosimilar Market
The pegfilgrastim biosimilar market is segmented into the following regions - North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa. North America is the dominant region that holds over 3/4 of the global pegfilgrastim biosimilar market share. Majority of pegfilgrastim biosimilar developers target North America for their product launches, owing to growing demand for biosimilars in this region.
North America has experienced increasing spending on biologics for cancer and related disease treatment over the past few years. Also, rising prevalence of cancer and advanced healthcare facilities make North America the most attractive region for pegfilgrastim biosimilar market players. The pegfilgrastim biosimilar market in the Asia Pacific region is likely to witness significant growth due to increasing prevalence of cancer coupled with lowering of prices owing to launch of various biosimilars. The adoption of originator pegfilgrastim (Neulasta) in Asia Pacific has remained limited due to higher cost of the product, resulting in limited accessibility.
To understand the regional dynamics of the pegfilgrastim biosimilar market, request a report sample
Pegfilgrastim Biosimilar Market: Key Players
The pegfilgrastim biosimilar market is significantly consolidated and competitive in nature. Many small and large pharmaceutical companies have developed this biosimilar. Key players operating in the market are Coherus Biosciences, Mylan N.V., Biocon, and Novartis AG (Sandoz). These companies have launched pegfilgrastim biosimilars and are bolstered with partnerships and collaborations for expanding their market presence, globally. Other players in the market are Pfizer Inc, Green Cross Corp, Accord healthcare, Intas Pharmaceuticals Ltd, and Zydus Cadila. These players are focused on strategic collaborations & partnerships and investments in research & development for developing novel biosimilar platforms.
For a dashboard view of key players operating in the pegfilgrastim biosimilar market, request a expert analyst
The Analyst’s Viewpoint
“Key players should target emerging markets along with developed markets to make the access of affordable biosimilar therapeutics easy for a large patient population, and, in turn, expand their global footprints.”
COVID-19 Impact on Pegfilgrastim Biosimilar market
COVID-19 has affected the pace of clinical trials, eventually leading to delays in the approval process. Delays caused by the COVID-19 pandemic crisis may lead to a backlog of approvals, and eventually delay the launches of 2020. Coherus Biosciences, a key manufacturer of pegfilgrastim biosimilar, mentioned that, the company does not import its active pharmaceutical ingredients (API) for UDENYCA from countries such as China and India, and therefore, its manufacturing did not get impacted by the coronavirus pandemic. The overall effect of the COVID-19 outbreak on the pegfilgrastim biosimilar market has been moderate.
Pegfilgrastim Biosimilar Market: About the Report
Fact.MR published an exclusive forecast report on the pegfilgrastim biosimilar market for 2020 to 2026. The foremost objective of this report on the pegfilgrastim biosimilar market is to pitch spearhead insights on the market scenario, demand generators, and product developments in the pegfilgrastim biosimilar market. Also, the study addresses key dynamics that are expected to diversify the sales and future prominence of pegfilgrastim biosimilars.
The report on the pegfilgrastim biosimilar market begins with an executive overview, in which, product definition has been provided. The report further proceeds with the taxonomy of the pegfilgrastim biosimilar market, elaborating on key segments. Also, the report outlines visionary insights on the dynamics of the pegfilgrastim biosimilar market, including the drivers, restraints, opportunities, trends, and developments for pegfilgrastim biosimilars. Current product pipeline analysis has also been included in the report, to help readers clearly understand the future product framework map in the pegfilgrastim biosimilar market.
Pegfilgrastim Biosimilar Market – Report Scope
Fact.MR recently published a market study on the global market for pegfilgrastim biosimilars. The study provides detailed assessment of key market dynamics, including the drivers, trends, opportunities, and restraints, as well as detailed information about the pegfilgrastim biosimilar market structure. The market study presents exclusive information about how the pegfilgrastim biosimilar market will grow during the forecast period (2020 to 2026).
Key indicators of market growth, which include year-on-year (Y-o-Y) growth of the market and compounded annual growth rate (CAGR) are explained in Fact.MR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the pegfilgrastim biosimilar market during the forecast period.
The study is relevant for stakeholders in the pegfilgrastim biosimilar market, including manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the pegfilgrastim biosimilar market, investors, industry experts, researchers, and journalists, as well as business researchers, can leverage the information and data presented in Fact.MR’s study.
It also offers actionable insights based on the future trends in the pegfilgrastim biosimilar market. Furthermore, small businesses and new entrants in the pegfilgrastim biosimilar market too can make use of the information presented in this study, based on which, they can make appropriate business decisions to gain momentum in the market.
Key Segments of Pegfilgrastim Biosimilar Market
Fact.MR’s study on the pegfilgrastim biosimilar market offers information divided into two important segments— distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories, for the better understanding of readers.
|
Distribution Channel |
Region |
|
|
Key Questions Answered in Fact.MR’s Pegfilgrastim Biosimilar Market Report
- Which regions will continue to remain the most profitable regional markets for pegfilgrastim biosimilar market players?
- Which factors will induce a change in the demand for pegfilgrastim biosimilars during the assessment period?
- How will changing trends impact the pegfilgrastim biosimilar market?
- What effect will the COVID-19 pandemic have on the global pegfilgrastim biosimilar Market
- How can market players capture the low-hanging opportunities in the pegfilgrastim biosimilar market in developed regions?
- Which companies are leading the pegfilgrastim biosimilar market?
- What are the winning strategies of stakeholders in the pegfilgrastim biosimilar market to upscale their position in this landscape?
Pegfilgrastim Biosimilar Market: Research Methodology
In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the pegfilgrastim biosimilar market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the pegfilgrastim biosimilar market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the pegfilgrastim biosimilar market, and makes Fact.MR’s projections on the growth prospects of the pegfilgrastim biosimilar markets more accurate and reliable.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Product Innovation / Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.2. Forecast Factors - Relevance & Impact
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis
5. COVID19 Crisis Analysis
5.1.1. Current COVID19 Statistics and Probable Future Impact
5.1.2. COVID-19 Impact on GDP
5.1.3. COVID-19 Impact of Pegfilgrastim Biosimilar Market
6. Market Context
6.1. Product Development
6.2. Product Adoption / Usage Analysis
6.3. Regulatory Scenario
6.4. Pipeline Assessment
7. Global Pegfilgrastim Biosimilar Market Value Analysis 2018-2019 and Forecast, 2019-2026
7.1. Historical Market Value (US$ Mn) Analysis, 2018-2019
7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2026
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026, by Distributional Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Distributional Channel, 2018-2019
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distributional Channel, 2020-2026
8.3.1. Hospital pharmacies
8.3.2. Retail pharmacies
8.3.3. Mail-Order pharmacies
8.4. Market Attractiveness Analysis By Distributional Channel
9. Global Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026, by Region
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2019
9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2026
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. East Asia
9.3.5. South Asia
9.3.6. Oceania
9.3.7. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019
10.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026
10.3.1. By Country
10.3.1.1. U.S.
10.3.1.2. Canada
10.3.2. By Application
10.3.3. By Distributional Channel
10.4. Market Attractiveness Analysis
10.5. Key Market Participants - Intensity Mapping
10.6. Drivers and Restraints - Impact Analysis
11. Latin America Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019
11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026
11.3.1. By Country
11.3.1.1. Brazil
11.3.1.2. Mexico
11.3.1.3. Argentina
11.3.1.4. Rest of Latin America
11.3.2. By Application
11.3.3. By Distributional Channel
11.4. Market Attractiveness Analysis
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
12. Europe Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026
12.3.1. By Country
12.3.1.1. Germany
12.3.1.2. Italy
12.3.1.3. France
12.3.1.4. U.K.
12.3.1.5. Spain
12.3.1.6. Russia
12.3.1.7. Rest of Europe
12.3.2. By Application
12.3.3. By Distributional Channel
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. South Asia Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026
13.3.1. By Country
13.3.1.1. India
13.3.1.2. Thailand
13.3.1.3. Indonesia
13.3.1.4. Malaysia
13.3.1.5. Rest of South Asia
13.3.2. By Application
13.3.3. By Distributional Channel
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. East Asia Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Application
14.3.3. By Distributional Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. Oceania Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026
15.3.1. By Country
15.3.1.1. Australia
15.3.1.2. New Zealand
15.3.2. By Application
15.3.3. By Distributional Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Middle East and Africa Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026
16.3.1. By Country
16.3.1.1. GCC Countries
16.3.1.2. South Africa
16.3.1.3. Rest of Middle East and Africa
16.3.2. By Application
16.3.3. By Distributional Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies
17.2. Market Concentration
17.3. Market Share Analysis of Top Players
17.4. Market Presence Analysis
17.4.1. By Regional footprint of Players
17.4.2. Product foot print by Players
17.4.3. Channel Foot Print by Players
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Competition Deep Dive
18.3.1. Mylan NV
18.3.1.1. Overview
18.3.1.2. Product Portfolio
18.3.1.3. Analyst Commentary
18.3.1.4. Key Financials
18.3.1.5. Recent Developments
18.3.1.6. Sales Footprint
18.3.1.7. Strategy Overview
18.3.1.7.1. Marketing Strategy
18.3.1.7.2. Product Strategy
18.3.1.7.3. Channel Strategy
18.3.2. Novartis AG
18.3.2.1. Overview
18.3.2.2. Product Portfolio
18.3.2.3. Analyst Commentary
18.3.2.4. Key Financials
18.3.2.5. Recent Developments
18.3.2.6. Sales Footprint
18.3.2.7. Strategy Overview
18.3.2.7.1. Marketing Strategy
18.3.2.7.2. Product Strategy
18.3.2.7.3. Channel Strategy
18.3.3. Coherus BioSciences
18.3.3.1. Overview
18.3.3.2. Product Portfolio
18.3.3.3. Analyst Commentary
18.3.3.4. Key Financials
18.3.3.5. Recent Developments
18.3.3.6. Sales Footprint
18.3.3.7. Strategy Overview
18.3.3.7.1. Marketing Strategy
18.3.3.7.2. Product Strategy
18.3.3.7.3. Channel Strategy
18.3.4. Mundipharma International
18.3.4.1. Overview
18.3.4.2. Product Portfolio
18.3.4.3. Analyst Commentary
18.3.4.4. Key Financials
18.3.4.5. Recent Developments
18.3.4.6. Sales Footprint
18.3.4.7. Strategy Overview
18.3.4.7.1. Marketing Strategy
18.3.4.7.2. Product Strategy
18.3.4.7.3. Channel Strategy
18.3.5. Biocon
18.3.5.1. Overview
18.3.5.2. Product Portfolio
18.3.5.3. Analyst Commentary
18.3.5.4. Key Financials
18.3.5.5. Recent Developments
18.3.5.6. Sales Footprint
18.3.5.7. Strategy Overview
18.3.5.7.1. Marketing Strategy
18.3.5.7.2. Product Strategy
18.3.5.7.3. Channel Strategy
18.3.6. Intas Pharmaceuticals Ltd.
18.3.6.1. Overview
18.3.6.2. Product Portfolio
18.3.6.3. Analyst Commentary
18.3.6.4. Key Financials
18.3.6.5. Recent Developments
18.3.6.6. Sales Footprint
18.3.6.7. Strategy Overview
18.3.6.7.1. Marketing Strategy
18.3.6.7.2. Product Strategy
18.3.6.7.3. Channel Strategy
18.3.7. Pfizer Inc.
18.3.7.1. Overview
18.3.7.2. Product Portfolio
18.3.7.3. Analyst Commentary
18.3.7.4. Key Financials
18.3.7.5. Recent Developments
18.3.7.6. Sales Footprint
18.3.7.7. Strategy Overview
18.3.7.7.1. Marketing Strategy
18.3.7.7.2. Product Strategy
18.3.7.7.3. Channel Strategy
18.3.8. Dr Reddy’s Laboratories
18.3.8.1. Overview
18.3.8.2. Product Portfolio
18.3.8.3. Analyst Commentary
18.3.8.4. Key Financials
18.3.8.5. Recent Developments
18.3.8.6. Sales Footprint
18.3.8.7. Strategy Overview
18.3.8.7.1. Marketing Strategy
18.3.8.7.2. Product Strategy
18.3.8.7.3. Channel Strategy
18.3.9. Zydus Cadila
18.3.9.1. Overview
18.3.9.2. Product Portfolio
18.3.9.3. Analyst Commentary
18.3.9.4. Key Financials
18.3.9.5. Recent Developments
18.3.9.6. Sales Footprint
18.3.9.7. Strategy Overview
18.3.9.7.1. Marketing Strategy
18.3.9.7.2. Product Strategy
18.3.9.7.3. Channel Strategy
18.3.10. Apotex Inc.
18.3.10.1. Overview
18.3.10.2. Product Portfolio
18.3.10.3. Analyst Commentary
18.3.10.4. Key Financials
18.3.10.5. Recent Developments
18.3.10.6. Sales Footprint
18.3.10.7. Strategy Overview
18.3.10.7.1. Marketing Strategy
18.3.10.7.2. Product Strategy
18.3.10.7.3. Channel Strategy
18.3.11. Emcure Pharmaceuticals Pvt Ltd.
18.3.11.1. Overview
18.3.11.2. Product Portfolio
18.3.11.3. Analyst Commentary
18.3.11.4. Key Financials
18.3.11.5. Recent Developments
18.3.11.6. Sales Footprint
18.3.11.7. Strategy Overview
18.3.11.7.1. Marketing Strategy
18.3.11.7.2. Product Strategy
18.3.11.7.3. Channel Strategy
18.3.12. USV Private Limited
18.3.12.1. Overview
18.3.12.2. Product Portfolio
18.3.12.3. Analyst Commentary
18.3.12.4. Key Financials
18.3.12.5. Recent Developments
18.3.12.6. Sales Footprint
18.3.12.7. Strategy Overview
18.3.12.7.1. Marketing Strategy
18.3.12.7.2. Product Strategy
18.3.12.7.3. Channel Strategy
18.3.13. Lupin
18.3.13.1. Overview
18.3.13.2. Product Portfolio
18.3.13.3. Analyst Commentary
18.3.13.4. Key Financials
18.3.13.5. Recent Developments
18.3.13.6. Sales Footprint
18.3.13.7. Strategy Overview
18.3.13.7.1. Marketing Strategy
18.3.13.7.2. Product Strategy
18.3.13.7.3. Channel Strategy
18.3.14. Kashiv Biosciences
18.3.14.1. Overview
18.3.14.2. Product Portfolio
18.3.14.3. Analyst Commentary
18.3.14.4. Key Financials
18.3.14.5. Recent Developments
18.3.14.6. Sales Footprint
18.3.14.7. Strategy Overview
18.3.14.7.1. Marketing Strategy
18.3.14.7.2. Product Strategy
18.3.14.7.3. Channel Strategy
18.3.15. Fresenius Kabi
18.3.15.1. Overview
18.3.15.2. Product Portfolio
18.3.15.3. Analyst Commentary
18.3.15.4. Key Financials
18.3.15.5. Recent Developments
18.3.15.6. Sales Footprint
18.3.15.7. Strategy Overview
18.3.15.7.1. Marketing Strategy
18.3.15.7.2. Product Strategy
18.3.15.7.3. Channel Strategy
18.3.16. Green Cross Corp
18.3.16.1. Overview
18.3.16.2. Product Portfolio
18.3.16.3. Analyst Commentary
18.3.16.4. Key Financials
18.3.16.5. Recent Developments
18.3.16.6. Sales Footprint
18.3.16.7. Strategy Overview
18.3.16.7.1. Marketing Strategy
18.3.16.7.2. Product Strategy
18.3.16.7.3. Channel Strategy
18.3.17. Jiangsu Hengrui Medicine Co., Ltd
18.3.17.1. Overview
18.3.17.2. Product Portfolio
18.3.17.3. Analyst Commentary
18.3.17.4. Key Financials
18.3.17.5. Recent Developments
18.3.17.6. Sales Footprint
18.3.17.7. Strategy Overview
18.3.17.7.1. Marketing Strategy
18.3.17.7.2. Product Strategy
18.3.17.7.3. Channel Strategy
19. Assumptions and Acronyms Used
20. Research Methodology
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Our Clients
Fact.MR in Media
Our analysts in Media
Pegfilgrastim Biosimilar Market Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2020 to 2026